Cyclacel Pharmaceuticals, Inc.

CYCC · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$1,397-$1-$0-$3,052
Dep. & Amort.-$1$0$0$1
Deferred Tax$0$0$0$0
Stock-Based Comp.-$1,671$0$2$93
Change in WC$9,535-$4,694-$4,841$1,602
Other Non-Cash-$4,961$3,639$1,592$0
Operating Cash Flow$4,298-$1-$3-$1,356
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0$0
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued-$5,313$1,921$3,646$1,613
Stock Repurch.$0$0$0$0
Dividends Paid$0-$0$0$0
Other Fin. Act.-$5,520-$41$0$1,612
Financing Cash Flow-$5,520$1,880$3,646$1,613
Forex Effect-$1$1-$86-$102
Net Chg. in Cash-$4,271$825$313$155
Supplemental Information
Beg. Cash$4,275$3$3,137$2,982
End Cash$4$4$3,450$3,137
Free Cash Flow$4,298-$1-$3-$1,356
Cyclacel Pharmaceuticals, Inc. (CYCC) Financial Statements & Key Stats | AlphaPilot